{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-25-004067","form_type":"8-K","ticker":"SLXN","cik":"0002022416","company_name":"Silexion Therapeutics Corp","filed_at":"2025-12-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.346656+00:00","generated_at":"2026-05-16T13:06:41.448554+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Silexion submits Phase 2/3 trial application for SIL204 in locally advanced pancreatic cancer","bullets":["Submitted Phase 2/3 clinical trial application in Israel for SIL204, a siRNA therapy for locally advanced pancreatic cancer (LAPC).","Phase 2/3 trial initiation planned for Q2 2026; follow-on regulatory filings in Germany/EU in Q1 2026.","Preclinical data demonstrated up to 99.7% cancer cell inhibition across multiple KRAS mutations.","Two completed species toxicology studies confirmed no systemic organ toxicity; positive German regulatory feedback received.","Collaborating with Sheba Medical Center (top-10 global hospital) for Israeli trial; U.S. expansion after safety run-in."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-25-004067","json":"https://secwatch.observer/filing/0001178913-25-004067.json","markdown":"https://secwatch.observer/filing/0001178913-25-004067.md","text":"https://secwatch.observer/filing/0001178913-25-004067.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022416/000117891325004067/0001178913-25-004067-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022416/000117891325004067/zk2534113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:06:41.448554+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}